Overview
Customizing Type 2 Diabetes Care According to Patient Characteristics and Needs
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Through a series of patient simulations, this learning experience offers healthcare providers an opportunity to evaluate patients’ medical history, current complaints, and laboratory tests to make clinical decisions related to the assessment, treatment, and management of patients with type 2 diabetes (T2D)/cardiovascular disease (CVD). Learners receive immediate feedback to evaluate how their decisions impact patient outcomes.
This activity is intended for primary care physicians, endocrinologists, diabetologists, and cardiologists who manage patients with type 2 diabetes practicing in Europe.
Recent updates to international guidelines provide an opportunity to educate physicians on the need to initiate appropriate therapy earlier for patients with T2D and coexisting cardio-renal-metabolic conditions, as well as intensify therapy when goals are not being met. Because over half of patients with T2D have either CVD or chronic kidney disease (CKD), and 4 in 5 patients have risk factors for diseases such as hypertension, dyslipidemia, and overweight/obesity, a shift from using only glycemia to guide treatment decisions to providing equal consideration to cardiorenal risk and weight management is paramount.
Upon completion of this activity, learners will be able to:
• Apply recent recommendations from evidence-based guidelines for the management of patients with type 2 diabetes, particularly in individuals with high cardiovascular risk or established atherosclerotic cardiovascular disease
• Align available type 2 diabetes agents with individual patient profiles, considering unique needs such as weight loss goals or the presence of cardiovascular disease
• Adapt management of cardiovascular risk factors in patients with type 2 diabetes using a comprehensive care approach considering factors such as glycaemic control, hypertension, dyslipidaemia and obesity/weight loss
• Recognize scenarios where a multidisciplinary approach is essential in the management of individuals with type 2 diabetes to ensure comprehensive care
• Address diverse patient needs, including cultural factors, through the management of type 2 diabetes using a shared decision-making approach
• Apply recent recommendations from evidence-based guidelines for the management of patients with type 2 diabetes, particularly in individuals with high cardiovascular risk or established atherosclerotic cardiovascular disease
• Align available type 2 diabetes agents with individual patient profiles, considering unique needs such as weight loss goals or the presence of cardiovascular disease
• Adapt management of cardiovascular risk factors in patients with type 2 diabetes using a comprehensive care approach considering factors such as glycaemic control, hypertension, dyslipidaemia and obesity/weight loss
• Recognize scenarios where a multidisciplinary approach is essential in the management of individuals with type 2 diabetes to ensure comprehensive care
• Address diverse patient needs, including cultural factors, through the management of type 2 diabetes using a shared decision-making approach
Provided by the Academy for Continued Healthcare Learning (ACHL) and Liberum IME.
Supported by an educational grant from Novo Nordisk.
Kare Birkeland, MD, PhD (Faculty)
Professor of Internal Medicine
University of Oslo
Oslo University Hospital
Oslo, Norway
Professor of Internal Medicine
University of Oslo
Oslo University Hospital
Oslo, Norway
Paola Fioretto, MD, PhD (Faculty)
Professor of Medicine, Nephrology
Department of Medicine
University of Padova
Padova, Italy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Kare Birkeland (Faculty)
Grants/Research Support: AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk, Roche
Speakers Bureau: Boehringer Ingelheim, Lilly, Novo Nordisk, Roche
Paola Fioretto, MD, PhD (Faculty)
Advisory Board: AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk
ACHL staff members, Liberum IME staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA and/or EMA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None
This activity will take approximately 30 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. A passing score of 80% on the posttest is required to receive credit. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
